FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:METTL25-ATP2B1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: METTL25-ATP2B1
FusionPDB ID: 53111
FusionGDB2.0 ID: 53111
HgeneTgene
Gene symbol

METTL25

ATP2B1

Gene ID

84190

490

Gene namemethyltransferase like 25ATPase plasma membrane Ca2+ transporting 1
SynonymsC12orf26PMCA1|PMCA1kb
Cytomap

12q21.31

12q21.33

Type of geneprotein-codingprotein-coding
Descriptionmethyltransferase-like protein 25plasma membrane calcium-transporting ATPase 1ATPase, Ca++ transporting, plasma membrane 1plasma membrane calcium pump
Modification date2020032020200322
UniProtAcc

Q8N6Q8

Main function of 5'-partner protein: FUNCTION: Putative methyltransferase. {ECO:0000250}.

P20020

Main function of 5'-partner protein: FUNCTION: Catalyzes the hydrolysis of ATP coupled with the transport of calcium from the cytoplasm to the extracellular space thereby maintaining intracellular calcium homeostasis. Plays a role in blood pressure regulation through regulation of intracellular calcium concentration and nitric oxide production leading to regulation of vascular smooth muscle cells vasoconstriction. Positively regulates bone mineralization through absorption of calcium from the intestine. Plays dual roles in osteoclast differentiation and survival by regulating RANKL-induced calcium oscillations in preosteoclasts and mediating calcium extrusion in mature osteoclasts (By similarity). Regulates insulin sensitivity through calcium/calmodulin signaling pathway by regulating AKT1 activation and NOS3 activation in endothelial cells (PubMed:29104511). {ECO:0000250|UniProtKB:G5E829, ECO:0000269|PubMed:29104511}.
Ensembl transtripts involved in fusion geneENST idsENST00000547357, ENST00000248306, 
ENST00000261173, ENST00000348959, 
ENST00000359142, ENST00000393164, 
ENST00000428670, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 5 X 2=607 X 7 X 4=196
# samples 67
** MAII scorelog2(6/60*10)=0log2(7/196*10)=-1.48542682717024
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: METTL25 [Title/Abstract] AND ATP2B1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: METTL25 [Title/Abstract] AND ATP2B1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)METTL25(82793173)-ATP2B1(90005149), # samples:1
Anticipated loss of major functional domain due to fusion event.METTL25-ATP2B1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
METTL25-ATP2B1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
METTL25-ATP2B1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
METTL25-ATP2B1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneATP2B1

GO:0051480

regulation of cytosolic calcium ion concentration

18029012

TgeneATP2B1

GO:1990034

calcium ion export across plasma membrane

18029012



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:82793173/chr12:90005149)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across METTL25 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ATP2B1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000248306METTL25chr1282793173+ENST00000348959ATP2B1chr1290005149-5621120062687893
ENST00000248306METTL25chr1282793173+ENST00000261173ATP2B1chr1290005149-5729120062795929
ENST00000248306METTL25chr1282793173+ENST00000359142ATP2B1chr1290005149-5878120062663885
ENST00000248306METTL25chr1282793173+ENST00000428670ATP2B1chr1290005149-5708120062795929
ENST00000248306METTL25chr1282793173+ENST00000393164ATP2B1chr1290005149-2938120062795929

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000248306ENST00000348959METTL25chr1282793173+ATP2B1chr1290005149-0.0001252350.9998747
ENST00000248306ENST00000261173METTL25chr1282793173+ATP2B1chr1290005149-0.0001057830.99989426
ENST00000248306ENST00000359142METTL25chr1282793173+ATP2B1chr1290005149-0.0001325050.99986744
ENST00000248306ENST00000428670METTL25chr1282793173+ATP2B1chr1290005149-0.0001071920.99989283
ENST00000248306ENST00000393164METTL25chr1282793173+ATP2B1chr1290005149-0.0003166680.9996834

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for METTL25-ATP2B1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
METTL25chr1282793173ATP2B1chr12900051491200398ADSELHDIIKDLEVPDAIKKCQRAGI

Top

Potential FusionNeoAntigen Information of METTL25-ATP2B1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
METTL25-ATP2B1_82793173_90005149.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
METTL25-ATP2B1chr1282793173chr12900051491200HLA-B13:01KDLEVPDAI0.76640.9543918
METTL25-ATP2B1chr1282793173chr12900051491200HLA-A66:01EVPDAIKKCQR0.99940.61211223
METTL25-ATP2B1chr1282793173chr12900051491200HLA-A26:03EVPDAIKKCQR0.99760.60611223
METTL25-ATP2B1chr1282793173chr12900051491200HLA-B39:08KDLEVPDAI0.3330.7687918

Top

Potential FusionNeoAntigen Information of METTL25-ATP2B1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
METTL25-ATP2B1_82793173_90005149.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
METTL25-ATP2B1chr1282793173chr12900051491200DRB1-0455HDIIKDLEVPDAIKK520
METTL25-ATP2B1chr1282793173chr12900051491200DRB1-0470HDIIKDLEVPDAIKK520
METTL25-ATP2B1chr1282793173chr12900051491200DRB1-1002HDIIKDLEVPDAIKK520
METTL25-ATP2B1chr1282793173chr12900051491200DRB1-1002LHDIIKDLEVPDAIK419
METTL25-ATP2B1chr1282793173chr12900051491200DRB1-1389DSELHDIIKDLEVPD116

Top

Fusion breakpoint peptide structures of METTL25-ATP2B1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
1148DIIKDLEVPDAIKKMETTL25ATP2B1chr1282793173chr12900051491200

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of METTL25-ATP2B1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN1148DIIKDLEVPDAIKK-7.15543-7.26883
HLA-B14:023BVN1148DIIKDLEVPDAIKK-4.77435-5.80965
HLA-B52:013W391148DIIKDLEVPDAIKK-6.80875-6.92215
HLA-B52:013W391148DIIKDLEVPDAIKK-4.20386-5.23916
HLA-A11:014UQ21148DIIKDLEVPDAIKK-7.5194-8.5547
HLA-A11:014UQ21148DIIKDLEVPDAIKK-6.9601-7.0735
HLA-A24:025HGA1148DIIKDLEVPDAIKK-7.52403-7.63743
HLA-A24:025HGA1148DIIKDLEVPDAIKK-5.82433-6.85963
HLA-B27:056PYJ1148DIIKDLEVPDAIKK-3.28285-4.31815
HLA-B44:053DX81148DIIKDLEVPDAIKK-5.91172-6.94702
HLA-B44:053DX81148DIIKDLEVPDAIKK-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of METTL25-ATP2B1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
METTL25-ATP2B1chr1282793173chr12900051491223EVPDAIKKCQRGAGGTGCCAGATGCAATTAAAAAGTGTCAGAGG
METTL25-ATP2B1chr1282793173chr1290005149918KDLEVPDAIAAAGATTTGGAGGTGCCAGATGCAATT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
METTL25-ATP2B1chr1282793173chr1290005149116DSELHDIIKDLEVPDGATTCAGAACTCCATGACATTATTAAAGATTTGGAGGTGCCAGAT
METTL25-ATP2B1chr1282793173chr1290005149419LHDIIKDLEVPDAIKCTCCATGACATTATTAAAGATTTGGAGGTGCCAGATGCAATTAAA
METTL25-ATP2B1chr1282793173chr1290005149520HDIIKDLEVPDAIKKCATGACATTATTAAAGATTTGGAGGTGCCAGATGCAATTAAAAAG

Top

Information of the samples that have these potential fusion neoantigens of METTL25-ATP2B1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SARCMETTL25-ATP2B1chr1282793173ENST00000248306chr1290005149ENST00000261173TCGA-DX-A48N-01A

Top

Potential target of CAR-T therapy development for METTL25-ATP2B1

check button Predicted 3D structure. We used RoseTTAFold.
278_METTL25-ATP2B1_t000_.e2e.pdb


check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneATP2B1chr12:82793173chr12:90005149ENST0000026117310201006_102701221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST0000026117310201040_106001221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000002611731020856_87601221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000002611731020883_90301221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000002611731020928_94801221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000002611731020972_99101221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST0000034895910191006_102701185.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST0000034895910191040_106001185.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000003489591019856_87601185.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000003489591019883_90301185.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000003489591019928_94801185.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000003489591019972_99101185.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST0000035914210211006_102701177.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST0000035914210211040_106001177.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000003591421021856_87601177.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000003591421021883_90301177.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000003591421021928_94801177.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000003591421021972_99101177.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST0000042867011211006_102701221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST0000042867011211040_106001221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000004286701121856_87601221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000004286701121883_90301221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000004286701121928_94801221.0TransmembraneHelical
TgeneATP2B1chr12:82793173chr12:90005149ENST000004286701121972_99101221.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result
METTL25chr1282793173ENST00000248306ATP2B1chr1290005149ENST00000261173
METTL25chr1282793173ENST00000248306ATP2B1chr1290005149ENST00000348959
METTL25chr1282793173ENST00000248306ATP2B1chr1290005149ENST00000359142

Top

Related Drugs to METTL25-ATP2B1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to METTL25-ATP2B1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource